
Supplementary Information

The positive feedback loop formed by Twist1, Prrx1, and Tenascin-C bi-stably activates fibroblasts

Yeo, et.al.




Supplementary Figure 1. Twist1 was co-expressed with TNC in cancer-associated fibroblast. shRNA-mediated depletion of TNC led to decreased colony formation and gel contraction abilities in stomach cancer-derived CAF (SCAF#39). Silencing of TNC also increased the proportion of apoptotic cells.


Species

HumanCAAAAAGTAAAGTGAGAATCCTGCTCTCTAATACATCTGChimpanzeeCAAAAAGTAAAGTGAGAATCCTGCTCTCTAATACATCTGCowCGAAAAGTAAAGTGAGAATCCTGCTCTCCAATACATCTGCowCGAAAAGTAAAGTGAGAATCCTGCTCTCCAATACATCTGCoadaagtaAaGTAAAGTGAGAATCCTGCTCTCCAATACATCTGCAAGACATCACCCTCTCCTGAAACTTTCorillaCAAAAAGTAAAGTGAGAATCCTGCTCTCTAATACATCTGCoadaagtaAaGTAAAGTGAGAATCCTGCTCTCTAATACATCTGCAAAAAGTAAAGTGAGAATCCTGCTCTCTAATACorangutanCAAAAAGTAAAGTGAGAATCCTGCTCTCTAATACATCTGCoadaagtaAaGTAAAGTGAGAATCCTGCTCTCTAATACATCTGCAAAAAGTAAAGTGAGAATCCTGCTCTCTAATAMouseCGAAAAGTAAAGTGAGAATCCTGCTCTCCAATACATCTGCoadaagtaAaGTGAGAATCCTGCTCTCCAATACATCTGCTGAAAATCCTCTGAAACTTTHorseCGAAAAGTAAAGTGAGAATCCTGCTCTCCAATACATCTGCaadaGTAAAGTAAAGTGAGAATCCTGCTCTCCAATACATCTGCAAGACATCACCCTCTCCTGAAACTTTCaaCGAAAAGTAAAGTGAGAATCCTGCTCTCCAATACATCTGCoadaaGTAAAGTGAGAATCCTGCTCTCCAATACATCTGCAAGACATCACCCTCTCCTGAAACTTTCaaCGAAAAGTAAAGTGAGAATCCTGCTCTCCAATACATCTGCabaAAGTAAAGTGAGAATCCTGCTCTCCAATACATCTGCAAGACATCACCCTCTCCTCCTGAAACTTTColphinCAAAAGTAAAGTGAGAATCCTGCTCTCCAATACATCTGColphinCAAAAGTAAAGTGAGAATCCTGCTCTCCAATACATCTGColphinCAAAAGTAAAGTGAGAATCCTGCTCTCTAATACATCTGColphinCAAAAGTAAAGTGAGAATCCTGCTCTCTAATACATCTGCondaaGTAAAGTGAGAATCCTGCTCTCTAATACATCTGCAAGACATCACCCTCTCCTCCTGCAAACTTT


Supplementary Figure 2. Conserved motifs in the Prrx1 promoter. Alignment of an E-box sequence CATCTG (in bold) for 12 species.




Supplementary Figure 3. Twist1, Prrx1, and TNC formed a positive feedback loop in fibroblasts. (a) Both Prrx1a and Prrx1b increased the mRNA level of TNC in normal fibroblasts (SNF#14, 32). The depletion of Prrx1 led to the down-regulation of mRNA levels of TNC in CAFs (SCAF#32, SCAF#39). Data are mean ± S.E.M;N=3 independent experiments.(P values, two-tailed t-test, ***p<0.001). Statistic source data for b and d are provided in Supplementary Table4. (b) Induction of Twist1 expression using Tet-On system led to sequential increases of Prrx1 and TNC mRNA expression in normal lung fibroblast (IMR#90), and normal gastric fibroblast(SNF#19)



Supplementary Figure 4. (a)Estimation of kinetic parameter values of the mathematical model_ based on temporal measurements of the fold change of Twist1, Prrx1, and TNC, for the doxycycline stimulus (100ng). Discrete data marked with circles, indicating experimental measurements of the corresponding genes (n=4, error bars indicate s.d.). The kinetic parameter values of the model were fitted to these experimental measurements. We confirmed that the simulation results are well in accord with the experimental data for 10% random perturbations of all the nominal parameter values (n=1000, error bars indicate s.d.).(b) The hysteretic responses of TNC to the doxycycline stimulus as the degradation rate of Twist1 decreases. The hysteretic curve shifts to the left along with the increase of the stability of Twist1, which leads to an irreversible state. (C)The hysteretic responses of TNC to the doxycycline stimulus_ along with the increase of the production rate of Twist1. As the expression level of Twist1 increases, the hysteretic curve shifts to the left and the hysteresis gets diminished.




Supplementary Figure 5. Gastric cancer derived CAFs (SCAF#39) were sorted into Twist1-positive and negative CAFs. Twist1-positive CAFs were specifically positive for Prrx1 and TNC. Twist1-positive CAFs also exhibited increased colony forming abilities



Supplementary Figure 6. Hyper-activation of fibroblasts and epithelial cells.


(a)TNC accumulation induced hyperplasia of both fibroblasts and epithelial cells. Acanthosis(Epithelial cells hyperplasia, blue dotted line), hyperkeratosis (a thick cornified layer), parakeratosis (presence of the nuclei in the cornified layer (red arrow)).

(b)Original IHC and multiple staining images of Fig6C,D and E.TNC-yellow, Twist1-green, Prrx1-red, He(Hematoxylin)-blue.





Supplementary Figure 7. Multiplex imaging analysis.

Original IHC and multiple staining images of Fig6C,D and E.TNC-yellow, Twist1-green, Prrx1-red, He(Hematoxylin)-blue.









 IPF#2
 Colon Cancer

 TNC/Hematoxylin
 TNC


 100m
 Twist1/Hematoxylin

 Prrx1/Hematoxylin
 Prrx1


 Hematoxylin
 Hematoxylin

f


Supplementary Figure 8. (a) Endogeneous mRNA levels of Twist1, Prrx1, TNC in various fibroblast models. (b) Analysis of RNA-SEQ data from TCGA revealed that there was a strong correlation among all three genes' expressions in various types of cancer. We downloaded the RNA-SEQ data of 1200 patients suffering from major cancer, from the homepage of The Cancer Genome Atlas (TCGA, https://cancergenome.nih.gov/). Next, we studied the correlation among three genes in a large population of cancer patients, using a public database. (c) Circos plot illustrated the results of gene set enrichment assay (GSEA). The RNA-SEQ data of 11 cancer types was obtained from TCGA. Then, Twist1/Prrx1/TNC (+/+/+) and Twist1/Prrx1/TNC (-/-/-) patients'- cohort groups were selected for each of the 11 cancer types. We then compared the gene expression patterns of both groups, and attempted to identify the specific signaling pathways enriched in the Twist1/Prrx1/TNC (+/+/+) group, by performing a gene set enrichment analysis (GSEA), using the Broad Institute's GSEA software (d) All three genes positive fibroblasts were frequently observed in pathologic fibrosis including keloid disease and desmoid tumors (aggressive fibromatosis). (e) Multiplex imaging analysis progressed from IPF#2 and Colon cancer patient tissue. Each Density/Area was measured using by image J Fiji (Twist1-green, Prrx1-red, TNC- yellow and Hematoxylin-blue). Data are mean ± S.E.M; N=3 independent measurements (P values, two-tailed t-test, *p<0.05, **p<0.001, ***p<0.0001). (f) Original IHC staining of IPF#2 and Colon cancer tissue.




Supplementary Figure 9. Hysteresis analysis of a coupled positive and negative feedback loop (a) Schematic diagram of the coupled Twist1-Prrx1-TNC PFL and NFL and the mathematical description of TNC and X. The state equations for Twist1 and Prrx1 are the same as those depicted in Fig. 4(a). (b) Temporal profiles of the fold change of Twist1, Prrx1, TNC, and X for the doxycycline stimulus (100ng). (c) and (d) Various profiles for the hysteretic response of TNC to the doxycycline stimulation along with the increase of negative (c) and positive (d) feedback strength. (e) Phase diagram illustrating the irreversibility of TNC with respect to the negative and positive feedback strength (see the detailed descriptions of the irreversibility of TNC in Fig. 4(e)).




Supplementary Figure 10. Mice genotyping. Representative gel run image. gDNAs were isolated from each mice ear or toes. (top) confirming FSP1-Cre, (bottom) Twist1 flox/flox .




Related to Figure 1 and supplementary Figure 1




Related to Figure 3



Related to Figure 5 and supplementary Figure 5



Related to Figure7



Antibodies

Twist1	Abcam, ab50887	1:1000(WB),1:200(IHC/IF), 1ug/ml(ChIP)
a-Tubulin	Santacruz, TU-02	1:3000(WB)
Tn-c	Abcam, ab108930	1:500(IHC/IF)
Tn-c	GENETEX, GTX62552	1:1000(WB)
Prrx1	sigma-aldrich, HPA051084	1:200(IHC/IF)
Prrx1	Origene, TA803116	1:1000(WB)
2nd goat anti-mouse-HRP	Santacruz, sc 2005	1 : 10000(W/B)
2nd goat anti-rabbit-HRP	Santacruz, sc 2004	1 : 10000(W/B)
Normal mouse IgG	Santacruz, sc2025	1ug/ml(ChIP)

For ChIP			
TNC primer 1	F: AGCAAAGTATGCCGTCGTCT	Prrx1 primer 1	F: TGCCTTTTGAAGTGCCA
	R: AGGCAGAAGATGGGGAAGAG		R: TCTTGCTGGGCTCCTTT
TNC primer2	F: ATCTGGACGACAGGCAGACT	N.C region	F: TGGATGGATGGATGGAT
	R: AGGCAGTGAAGGGACTAGCA		R: GTAGGTGTCTTCTGTGCATT
TNC primer 3	F: GACATCTCAGGGCCGAAAAC	P.C PDGFRa	F : GCACTATCCCTGGAGTCAGC
	R: CGGCGCTTGGAGTGATAGAA		R : CACCCAGTTGTCCTTCTGGT
TNC primer 4	F: CCAAGAAGGGCCAGTCTACGT		
	R: GCCCCACTTTCTTGATCATTG		

For RT-PCR	Sequences
Twist1	F : TCCAGAGAAGGAGAAAATGGA
	R : CCCACGCCCTGTTTCTTTGA
Prrx1	F: CAGGCGGATGAGAACGTGG
	R: AAAAGCATCAGGATAGTGTGTCC
Tn-C	F: TCCCAGTGTTCGGTGGATCT
	R: TTGATGCGATGTGTGAAGACA
GAPDH	F: GCACCGTCAAGGCTGAGAA
	R: AGCATCGCCCCACTTGATT

For Cloning	
Twist1 lentiviral cloning (BamHI/Xh	
	R: ATTCTCGAGCTAGTGGGACGCGGACATG
Prrx1a lentiviral cloning (BamHI/Xh	cF: ATTGGATCCATGACCTCCAGCTACGGG
	R: ATTCTCGAGTCAGTTGACTGTTGGCACCTG
Prrx1b lentiviral cloning (BamHI/Xh	ICF: ATTGGATCCATGACCTCCAGCTACGGG
	R: ATTCTCGAGTCAGTTGACTGTTGGCACCTG
TNC lentiviral cloning (BglII/sall)	F: ATTAGATCTATGGGGGCCATGACT
	R: ATTGTCGACTTATGCCCGTTTGCG
shTwist1-2	CCGGCCTGAGCAACAGCGAGGAAGACTCGAG TCTTCCTCGCTGTTGCTCAGGTTTTTG
shNS	CCGGCAACAAGATGAAGAGCACCAACTCGAG TTGGTGCTCTTCATCTTGTTGTTTTG
shPrrx1-5	CCGGGCAGGCTTTGGAGCGTGTCTTCTCGAGAAGAC ACGCTCCAAAGCCTGCTTTTTG
shPrrx1-6	CCGGAGCAGCGAAGGAATAGGACAACTCGAGTTGTCCTA TTCCTTCGCTGCTTTTTG
shTenascin-C	CCGGGGAGTACTTTATCCGTGTATTCTCGAGAATACACG GATAAAGTACTCCTTTTTG

For luciferase & muta	nt assay
pGL3.Prrx1 (650bp)	F: ATTATCGATTGAAACTTTAGTCACTCCTGAGAATC
	R: ATTACGCGTGCTCGAATCAACACCAAA
pGL3.Prrx1(850bp)	F: ATTGGTACCGCTTCTTGATCCAACTGAGA
	R: ATTACGCGTGCTCGAATCAACACCAAA
pGL3.Prrx1(1.2kb)	F: ATTATCGATTCAGTTTGTCTTTTCTCCCCGT
	R: ATTACGCGTGCTCGAATCAACACCAAA
pGL3.Prrx1(3.2kb)	F: ATTGGTACCCCACACCTTTGTCACGAC
	R: ATTACGCGTGCTCGAATCAACACCAAA
E-BOX 1 mutant	F: CTGCTCTCTAATAGGTCTGCAAGACATC
	R: GATGTCTTGCAGACCTATTAGAGAGCAG
E-BOX 2 mutant	F: CCAGAGAGCTTCTTGATCTCACTGAGAAGGAAAAAGG
	R: CCTTTTTCCTTCTCAGTGAGATCAAGAAGCTCTCTGG

	Circos plot GSEA			
Cancer Type	Pathway	NES	p-val F	DR-qval
Colon adenocarcinoma	Angiogenesis	2.182591	0	(
	Epithelial mesenchymal transition	2.117569	0	2.57E-04
	Extracellular matrix organization	2.098079	0	0.002854
	Apoptosis	1.931974	0	0.005136
	P53	1.961539	0	0.002719
Stomach cancer	Angiogenesis	1.953737	0.006148	0.007915
	Epithelial mesenchymal transition	2.302105	0	(
	Extracellular matrix organization	2.118408	0.00189	0.001771
	Apoptosis	1.796946	0.006356	0.021135
	P53	1.999769	0.001942	0.003431
Lung squamous cell carcinoma	Angiogenesis	1.870668	0	0.029496
	Epithelial mesenchymal transition	2.350822	0	(
	Extracellular matrix organization	2.250397	0	5.29E-04
Esophageal squamous cell carcinoma	Angiogenesis	2.044959	0	0.006631
	Epithelial mesenchymal transition	2.200889	0	(
	Extracellular matrix organization	2.084637	0	0.014955
	P53	1.799126	0.004032	0.028508
Head and Neck cancer	Angiogenesis	2.01363	0	0.003906
	Epithelial mesenchymal transition	2.170273	0	(
	Extracellular matrix organization	2.424593	0	(
Breast cancer	Angiogenesis	2.024872	0	9.80E-04
	Epithelial mesenchymal transition	2.178462	0	(
	Extracellular matrix organization	2.048585	0	0.002303
	Apoptosis	1.994614	0	0.00133
	P53	1.985845	0	9.43E-04
Endometrial cancer	Angiogenesis	2.107126	0	0.002851
	Epithelial mesenchymal transition	2.432389	0	(
	Extracellular matrix organization	2.27104	0	0.003206
	P53	1.727642	0	0.021373
Melanoma	Angiogenesis	1.938769	0	0.013485
	Epithelial mesenchymal transition	2.234258	0	(
	Extracellular matrix organization	2.087661	0	0.045073
Pancreatic cancer	Angiogenesis	1.875206	0.00216	0.007089
	Epithelial mesenchymal transition	2.009837	0	0.004285
	Extracellular matrix organization	1.983033	0	0.004813
	Apoptosis	1.902175	0.001972	0.004978
	P53	1.952217	0	0.001351
Prostate cancer	Epithelial mesenchymal transition	1.71524	0	0.040288
	Extracellular matrix organization	1.904468	0.002049	0.032039
	Apoptosis	1.705068	0.005906	0.037308
	P53	1.920413	0	0.005891
Renal cell carcinoma	Angiogenesis	2.218367	0	(
	Epithelial mesenchymal transition	2.218367	0	(
	Extracellular matrix organization	2.293175	0	(
	Apoptosis	1.889164	0.00188	0.014866
Rectal cancer	Angiogenesis	1.96879	0.00100	0.005118
	Epithelial mesenchymal transition	2.320097	0	(
	Apoptosis	1.924187	0.00202	0.007461
	P53	2.131963	0.00202	4.81E-04
Uterine Cervical cancer	Angiogenesis	1.831947	0.007273	0.030457
	Epithelial mesenchymal transition	2.140448	0.007273	0.000-101
	Extracellular matrix organization	2.072113	0	0.009493

Parameter estimates of the mathematical model.

ng ⁻¹ •hr ⁻¹ hr ⁻¹	6.053E+01 9.348E+00
hr ⁻¹	0.248E+00
	7.340E+UU
hr-1	2.997E+01
-	3.201E+00
hr ⁻¹	9.349E+00
-	9.000E+00
hr-1	1.503E+01
hr-1	1.400E+01
-	6.597 E+00
hr ⁻¹	1.503E+01
-	5.000E+00
hr-1	2.400E-03
hr-1	1.507E+01
-	1.256E+01
	hr ⁻¹

K_{TNC}^{-}	hr ⁻¹	1.000E-02
		3.000E+00

Supplementary Note 1

Mathematical model of the Twist1/Prrx1/TNC PFL

We developed a mathematical model of the Twist1/Prrx1/TNC PFL. For this model, we did not attempt to describe the exact *in silico* replica of all biochemical species and their interactions. Instead, we constructed a minimal essential model of the PFL by including only the three major components of it. From our own experimental observations, we confirmed the functional existence of a positive feedback loop formed by these three components: (i) Up-regulation of Twist1 in normal fibroblasts induced both the expression and stabilization of Prrx1; (ii) Prrx1 enhanced both mRNA and protein levels of TNC in normal fibroblasts; (iii) Exogeneous TNC increased Twist1 expression in normal fibroblast. Therefore, we described the regulatory mechanism among these three components based on Michaelis-Menten kinetics. The mathematical description of Twist1 ([Tw]), Prrx1 ([Pr]), and TNC ([TNC]) is summarized in equations (1) to (3) as follows:

$$\frac{d[\mathrm{Tw}]}{dt} = K_{in}[\mathrm{input}] + K_{Tw}^{+} + V_{TNC \to Tw} \frac{[\mathrm{TNC}]^{n1}}{K_{m1}^{n1} + [\mathrm{TNC}]^{n1}} - K_{Tw}^{-}[\mathrm{Tw}]$$
(1)

$$\frac{d[\Pr]}{dt} = K_{\Pr}^{+} + V_{Tw \to \Pr} \frac{[\operatorname{Tw}]^{n2}}{K_{m2}^{n2} + [\operatorname{Tw}]^{n2}} - K_{\Pr}^{-}[\Pr]$$
(2)

$$\frac{d[\text{TNC}]}{dt} = K_{TNC}^{+} + V_{\text{Pr}\to TNC} \frac{[\text{Pr}]^{n3}}{K_{m3}^{n3} + [\text{Pr}]^{n3}} - K_{TNC}^{-}[\text{TNC}]$$
(3)

In equation (1), K_{in} represents the rate constant of the Twist1 production promoted by the doxycycline input. We assumed that the exogenous doxycycline follows the hyperbolic tangent function as follows: $[input] = [doxy] \tanh(t/td)$ where td = 20 hours. $K^+_{Tw/Pr/TNC}$ and $K_{Tw/Pr/TNC}$ represents the basal production and degradation rate constants for the three genes. In the equation (1), $V_{TNC->Tw}$, K_{m1} and n_1 represent the maximal production rate, the Michaelis-Menten constant, and the Hill coefficient for activation of Twist1, respectively. Similarly, $V_{T_{W^*}>P_r}$, K_{m2} and n_2 are for Prrx1; $V_{Pr^*>TNC}$, K_{m3} and n_3 are for TNC. To estimate appropriate parameter values that can reproduce the fold change of the three genes as observed in our experiments, the levels of state variables were normalized by the basal levels of them such that all the state variables have the initial value of '1' at t=0. To investigate the underlying mechanism of persistent activation of PFL upon injection of high TNC, we modified the equation (1) such that the TNC injection induces the expression of Twist1, as follows:

$$\frac{d[\mathrm{Tw}]}{dt} = K_{in} \frac{[\mathrm{input}]^{n4}}{K_{m4}^{n4} + [\mathrm{input}]^{n4}} + K_{Tw}^{+} + V_{TNC \to Tw} \frac{[\mathrm{TNC}]^{n1}}{K_{m1}^{n1} + [\mathrm{TNC}]^{n1}} - K_{Tw}^{-}[\mathrm{Tw}].$$

Using this modified model, we estimated again the parameter values such that the level of Twist1 and TNC is in accord with the experimental observation along with the increase of recombinant TNC concentration (Figure 7b).

Parameter estimation

Our model consists of three state variables and 16 kinetic parameters. The kinetic parameter values were estimated based on our own time course measurements by using the genetic algorithm (GA) implemented in Matlab ToolboxTM. Parameter estimation was carried out based on maximum likelihood estimation, starting from some initial guess to find the optimal parameter estimates that minimize the difference between experimental data and simulated data obtained from the mathematical model. The cost function (J) for parameter estimation is defined by

$$J(\boldsymbol{p}) = \sum_{j=1}^{M} \sum_{i=1}^{N} (\bar{y}_{j,i} - y_j(t_i, \boldsymbol{p}))^2$$
, where *M* is the number of given experimental data and *N* is the

number of time points of each experimental data. The output of the mathematical model $y_j(t_i, p)$ is the value of the solution y_j of the ordinary differential equation (ODE) at t_i with parameter set p and $y_{j,i}$ is the mean of given repeated measurements of signaling molecules corresponding to y_j at t_i . All the parameter estimates are summarized in Supplementary Table4.